Compare Flux Power Holdings Inc (FLUX) vs Heron Therapeutics Inc (HRTX) Price & Performance

FLUX trades at $0.689, down 3.85% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $6.67 million in 2025 and a negative net income margin of -12.48% in 2026, though revenue remains substantial. Recent news highlights product innovation with the launch of SkyEMS 3.0 and new executive appointments aimed at growth. Analyst consensus is unanimously bullish with 6 buy ratings.

The outlook is mixed: strong analyst support and strategic developments offer upside potential, but persistent losses and bearish technicals pose significant risks. Investors must weigh growth initiatives against profitability challenges and market volatility.

Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.

HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.